INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 183 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2014. The put-call ratio across all filers is 1.68 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $831,000 | -56.3% | 59,552 | -56.7% | 0.13% | -25.0% |
| Q2 2022 | $1,900,000 | -13.0% | 137,596 | +2.5% | 0.17% | -10.6% |
| Q1 2022 | $2,183,000 | +443.0% | 134,182 | +444.2% | 0.19% | +506.5% |
| Q4 2021 | $402,000 | -82.4% | 24,657 | -78.5% | 0.03% | -79.5% |
| Q2 2021 | $2,287,000 | -10.4% | 114,515 | +3.5% | 0.15% | -17.5% |
| Q1 2021 | $2,552,000 | -1.2% | 110,592 | +5.7% | 0.18% | +4.6% |
| Q4 2020 | $2,584,000 | -40.6% | 104,604 | -0.2% | 0.18% | -39.0% |
| Q3 2020 | $4,347,000 | -36.2% | 104,846 | +94.4% | 0.29% | +1.4% |
| Q3 2018 | $6,815,000 | +193.5% | 53,932 | +94.9% | 0.28% | +221.6% |
| Q2 2018 | $2,322,000 | -57.4% | 27,672 | +20.3% | 0.09% | -38.0% |
| Q3 2014 | $5,446,000 | – | 23,011 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |